Opinions Jim Cramer - Mad Money
Prometheus BiosciencesRXDXBUYDec 09, 2022
They make drugs to treat inflammatory bowel diseases, a big market. Last Wednesday they announced strong phase 2 trial data for a leading IBD drug. Shares soared 166% on Wednesday. This drug will mae RXDX a major pharma.
Jim Cramer - Mad MoneyUnknown
$110.20
Stock price when the opinion was issued
$199.92
As of Jun 15, 2023. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
